SOUTH SAN FRANCISCO, Calif. — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate IDE161,...
Latest News
SOUTH SAN FRANCISCO, Calif. – IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced dose expansion of the ongoing Phase 1/2 study (ClinicalTrials.gov Identifier: NCT03947385) evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma (MUM). ...
SOUTH SAN FRANCISCO, Calif. — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the initiation of a Phase 1/2 expansion in the clinical trial evaluating IDE397, its investigational, potential first-in-class, small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, in combination...
PARMA, Italy and BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the US Food and Drug Administration (FDA) is evaluating the regulatory submission of idebenone to treat Leber Hereditary...
Baltimore, Maryland – Repeats of DNA sequences, often referred to as “junk DNA” or “dark matter,” that are found in chromosomes and could contribute to cancer or other diseases have been challenging to identify and characterize. Now, investigators at the Johns Hopkins Kimmel Cancer Center have developed a novel approach that uses...
GUANGZHOU, China — Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive...
Rio de Janeiro, Brazil – D’Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small...
PHILADELPHIA – iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has appointed Brian Di Donato, MBA to its Board of Directors. Mr. Di Donato has more than 20 years of financial and leadership experience and currently serves as...
PHILADELPHIA, PA – iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) of the company’s Clinical Trial Authorisation...
PHILADELPHIA, PA — iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that additional data from the ongoing OTC-HOPE clinical trial evaluating its candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency...